OAC
NMRA icon

OMERS Administration Corp’s Neumora Therapeutics NMRA Stock Holding History

OMERS Administration Corp’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.3K Sell
50,900
-86,400
-63% -$224K ﹤0.01% 1019
2025
Q4 		$246K Buy
+137,300
New +$301K ﹤0.01% 864

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

OMERS Administration Corp's NMRA Position: Q1 2026 in Review

OMERS Administration Corp reduced its Neumora Therapeutics (NMRA) stake by 63% in Q1 2026, selling an estimated $224K and leaving 50,900 shares worth $99.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1019.

OMERS Administration Corp first reported a position in NMRA in Q4 2025 and has held it in 2 quarters since. The position peaked at $246K in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • OMERS Administration Corp held 50,900 shares of Neumora Therapeutics worth $99.3K as of Q1 2026.
  • OMERS Administration Corp sold 86,400 Neumora Therapeutics shares in Q1 2026, an estimated $224K.
  • Neumora Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #1019 holding.
  • OMERS Administration Corp first reported a position in Neumora Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Neumora Therapeutics position peaked at $246K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.